Okorie Okorocha, J.D., M.S., M.S. • Attorney • Forensic Toxicologist • Expert Witness
Serious representation when medicine, drugs, alcohol, toxicology, or complex scientific evidence can determine the outcome.
When the case depends on the science, your lawyer should understand the science.
Forensic toxicology expert witness
Drug and alcohol evidence can appear definitive while leaving critical scientific questions unresolved. Forensic-toxicology analysis may address specimen integrity, analytical methodology, pharmacology, claimed impairment, measurement uncertainty, laboratory limitations, and whether the stated conclusion follows from the available data.
Where science meets the courtroom
Drug and alcohol evidence can look definitive while leaving critical questions unanswered. Analysis may require review of specimen integrity, analytical methodology, pharmacology, impairment, measurement uncertainty, laboratory limitations, and whether the conclusion actually follows from the data.
Serious-felony matters
The criminal-defense practice is limited to serious felony matters, including murder or manslaughter, sex-crime, and white-collar allegations. Forensic, toxicological, medical, and other scientific evidence is evaluated when relevant.
Civil representation
Personal injury, wrongful death, catastrophic injury, employment, and civil-rights matters can turn on medical causation, toxicology, drug or alcohol evidence, laboratory findings, and competing expert opinions.
Board and State Bar matters
Defense of attorneys, physicians, nurses, dentists, pharmacists, and other California licensees facing complaints, investigations, Accusations, disciplinary hearings, probation, or reinstatement.
Science-backed litigation resources
Use the Evidence Library for focused technical topics, ForensicToxicology.com for broader educational and research material, and The Okorocha Firm for representation, consultation, and expert-witness retention.
For expert-witness consultation or legal representation involving complex scientific evidence, call (424) 363-3347.
A receptor mutation delayed tolerance to WIN55,212-2 more consistently than to CP55,940, and the result also depended on how tolerance was measured. Fixed-dose behavior and dose-response shifts were different tests. Two agonists and several endpoints Investigators compared desensitization-resistant S426A/S430A mice with controls in thermal, formalin and chemotherapy-neuropathy experiments. Both challenge…
Read Article: A CB1 Mutation Changed Cannabinoid Tolerance Differently Across Testing Methods
Two FAAH inhibitors suppressed pain-related behavior during treatment, but neuropathy emerged after restricted preventive dosing stopped. Delaying an endpoint was not the same as permanently preventing the condition. Indirect cannabinoid-system modulation Researchers compared brain-permeant URB597, peripherally restricted URB937 and a direct synthetic agonist in paclitaxel-treated mice. FAAH inhibition alters endogenous…
Read Article: Endocannabinoid Enzyme Inhibition Delayed Neuropathy Without Permanently Preventing It
A study of GPR55 activation changed experimental barrier measurements, but its test substance was lysophosphatidylinositol, not THC. A cannabinoid-related receptor label cannot substitute for the actual exposure. Cells and animals answered different questions Researchers examined rat brain microvascular endothelial cells using calcium, electrical-resistance and junction-related measurements. Animal experiments also assessed…
Read Article: A GPR55 Barrier Study Did Not Demonstrate THC-Induced Blood–Brain Barrier Injury
